Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema

Long-Term Safety Evaluation of Continuous Intraocular Delivery of Aflibercept by the Intravitreal Gene Therapy Candidate ADVM-022 in Nonhuman Primates

(2021) Szilárd Kiss et al.   Translational Vision Science & Technology

Analysis of Aflibercept Expression in NHPs following Intravitreal Administration of ADVM-022, a Potential Gene Therapy for nAMD

(2020) Szilárd Kiss et al.   Molecular Therapy-Methods & Clinical Development

PHARMACOKINETIC STUDY OF INTRAVITREAL AFLIBERCEPT IN HUMANS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

(2019) Diana V. Do et al.   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

The primate model for understanding and restoring vision

(2019) Serge Picaud et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Diabetic Retinopathy: Pathophysiology and Treatments

(2018) Wei Wang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Preclinical Evaluation of ADVM-022, a Novel Gene Therapy Approach to Treating Wet Age-Related Macular Degeneration

(2018) Ruslan Grishanin et al.   MOLECULAR THERAPY

Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration

(2017) Jessica Boyle et al.   Psychology Health & Medicine

Treatment Burden in Neovascular AMD:Visual Acuity Outcomes are Associated With Anti-VEGF Injection Frequency

(2017) Rehan M. Hussain et al.   Ophthalmic Surgery Lasers & Imaging Retina

Systemic Safety of Prolonged Monthly Anti–Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema

(2016) Robert L. Avery et al.   JAMA Ophthalmology

Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting

(2015) E. Boulanger-Scemama et al.   JOURNAL FRANCAIS D OPHTALMOLOGIE

The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal disease

(2015) Richard L. Sidman et al.   Science Translational Medicine

Serum and Plasma Vascular Endothelial Growth Factor Concentrations Before and After Intravitreal Injection of Aflibercept or Ranibizumab for Age-Related Macular Degeneration

(2014) Xiying Wang et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Clinical Utilization of Anti-VEGF Agents and Disease Monitoring in Neovascular Age-Related Macular Degeneration

(2014) Nancy M. Holekamp et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD

(2014) Robert L Avery et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema

(2013) Claus Zehetner et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

In Vivo-Directed Evolution of a New Adeno-Associated Virus for Therapeutic Outer Retinal Gene Delivery from the Vitreous

(2013) D. Dalkara et al.   Science Translational Medicine

Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life

(2012) Katharina M. Droege et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration

(2012) Jeffrey S. Heier et al.   OPHTHALMOLOGY

Prevention of Experimental Choroidal Neovascularization and Resolution of Active Lesions by VEGF Trap in Nonhuman Primates

(2011) T. Michael Nork   ARCHIVES OF OPHTHALMOLOGY

Optimization of laser-induced choroidal neovascularization in African green monkeys

(2011) Robin J. Goody et al.   EXPERIMENTAL EYE RESEARCH